[Form 4] Vor Biopharma Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jean-Paul Kress, CEO, Chairman and Director of Vor Biopharma, was granted a significant stock option award on June 26, 2025. The derivative securities transaction involved 83,296,638 stock options with the following key terms:

• Exercise price set at $0.89 per share
• Options expire on June 25, 2035
• Vesting schedule: 25% vests on June 26, 2026, with remaining 75% vesting in equal monthly installments over 3 years
• Vesting contingent on continued service with company

This substantial equity grant aligns the CEO's interests with shareholders and suggests long-term commitment to the company. The low exercise price relative to typical biotech stock prices may indicate recent market challenges or strategic compensation planning.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kress Jean-Paul

(Last) (First) (Middle)

C/O VOR BIOPHARMA INC.

100 CAMBRIDGEPARK DRIVE, SUITE 101

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.89	06/26/2025		A		83,296,638		(1)	06/25/2035	Common Stock	83,296,638	$0	83,296,638	D

Explanation of Responses:

1. 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.

	/s/ Sherell Bacchas, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did VOR's CEO Jean-Paul Kress receive on June 26, 2025?

VOR's CEO and Chairman Jean-Paul Kress received 83,296,638 employee stock options with an exercise price of $0.89 per share on June 26, 2025.

What is the vesting schedule for VOR CEO's new stock options granted in June 2025?

The stock options vest over 4 years, with 25% vesting on June 26, 2026 (one year after grant), and the remaining 75% vesting in equal monthly installments over the following 3 years, subject to continued service.

When do VOR CEO Jean-Paul Kress's June 2025 stock options expire?

The stock options granted to Jean-Paul Kress on June 26, 2025, expire on June 25, 2035, giving him a 10-year period to exercise the options.

What is the exercise price of VOR's stock options granted to CEO in June 2025?

The exercise price of the stock options granted to VOR's CEO is $0.89 per share.

What positions does Jean-Paul Kress hold at VOR Biopharma as of June 2025?

According to the Form 4 filing, Jean-Paul Kress serves as both CEO and Chairman of the Board at VOR Biopharma Inc.